The world faces a new threat: superbugs resistant to most or even all existing antibiotics. These are mutated bacterial strains that have developed antibiotic resistance due to the excessive and often unjustified use of antimicrobials in human medicine, veterinary medicine, and agriculture. Infections caused by such microorganisms are increasingly becoming deadly, even in countries with high levels of healthcare.
Against this backdrop, interest in alternatives to antibiotics is growing, and phages are increasingly being viewed as a promising tool against superbugs.
One of the most impressive aspects of these viruses is their ability to precisely target pathogenic bacteria. Unlike antibiotics, which often destroy beneficial microflora as well, bacteriophages act selectively. This offers hope for an effective fight against superbugs, which are resistant to all known antibiotics.
Phages are known to infect bacteria with mutations that make them resistant to pharmaceuticals. Moreover, phages remain effective even when antibiotics fail. This is confirmed by both laboratory experiments and clinical cases of patients whose lives these viruses have literally saved.
One of the most high-profile cases occurred in the United States: a man with an Acinetobacter baumannii infection fell into a coma after all antibiotics proved ineffective. After receiving an experimental phage preparation, his condition began to improve, and he eventually recovered. This case proved that phages against superbugs are not just a hypothesis, but a real possibility.
Similar results have been obtained in France, Poland, Georgia, and other countries where phage therapy is already being actively integrated into healthcare systems. Successful examples of phage use against methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella, and Pseudomonas aeruginosa all demonstrate their practical benefits.
This is a fair and logical question. Yes, bacteria can mutate against phages. However, these viruses have an advantage: they, too, are capable of changing and adapting. It's a kind of arms race—bacteriophages adapt to changes in bacteria faster than scientists can create new antibiotics.
Furthermore, the combined use of multiple bacteriophages (so-called cocktails) significantly reduces the risk of resistance. When a single bacterium is attacked from multiple sides simultaneously, its chances of survival are minimal.
Modern science is developing the development of personalized phage preparations—where a patient's bacterial sample is tested and the appropriate virus is selected. This increases treatment effectiveness and minimizes side effects. The possibility of genetically modifying phages to enhance their effectiveness is also being explored.
Equally important, bacteriophages can be applied locally—for example, to wounds or nasopharyngeal infections—allowing them to act without harming the body as a whole.
Pharmaceutical companies in the US, UK, Israel, and Georgia are already investing in the development and production of new phage drugs that are expected to replace or complement antibiotics in the near future.
So, bacteriophages can destroy superbugs. They are already doing so in a number of clinical situations. All that's needed is to develop the scientific base, create the infrastructure for phage production, and train doctors to work with these unique biological agents.
Bacteriophages against superbugs are not science fiction, but a new stage in medicine that offers hope where chemicals have already failed. And with each passing year, this hope becomes more and more justified.